The invention features polypeptides that include an extracellular ActRIIa variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIa variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, e.g., Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia; or cancer cachexia; or metabolic diseases, e.g., obesity, Type-1 diabetes, or Type-2 diabetes.

The invention features polypeptides that include an extracellular ActRIIa variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIa variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, e.g., Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia; or cancer cachexia; or metabolic diseases, e.g., obesity, Type-1 diabetes, or Type-2 diabetes.

Abstract The disclosure provides a reagent comprising a leuco dye and a compound represented by Formula (I): ##STR00001## where R represents a hydrocarbon chain having 8 to 17 carbon atoms, the reagent for measuring glycoprotein, a kit comprising the reagent and a second reagent, and methods of measuring hemoglobin A1c using the reagent.

Abstract The disclosure provides a reagent comprising a leuco dye and a compound represented by Formula (I): ##STR00001## where R represents a hydrocarbon chain having 8 to 17 carbon atoms, the reagent for measuring glycoprotein, a kit comprising the reagent and a second reagent, and methods of measuring hemoglobin A1c using the reagent.

The present disclosure provides methods for producing consumable recombinant proteins that are substantially free from herein-disclosed undesired byproducts.

New proteophospholiposomes contain HDL-like vesicles with a new composite of anionic polypeptides, selected from the group of apoproteins A and at least one anionic polypeptide from the group of albumins, transthyretin-prealbumins and at least one cysteine group. The new anionic polypeptide composite is coated with layers of acyl-phosphatidylcholines that are protected from conversions by means of thio-phosphatidylcholines. The thiogroups attract antioxidants, ionic micromaterials and cofactors and are protected by exterior layers that contain neutral lipids and/or by means of capsules that contain microsomes, in an outwardly uniform fashion.

Disclosed herein are methods and compositions including casein, and methods for making these compositions.

Disclosed herein are methods and compositions including casein, and methods for making these compositions.

A product and method of using albumin nanoparticles for treating multiple traumas by augmenting the function or effectiveness of stem cells or precursor cells in vivo. An albumin nanoparticle suspension containing submicron albumin spheres is prepared, with the albumin spheres being capable of augmenting a function and effectiveness of stem cells or precursor cells in vivo for treating multiple traumas at the same time. A predetermined amount of the albumin nanoparticle suspension is administered to a patient before or after an onset of multiple traumas. A function of the stem or precursor cells can be augmented or improved by the albumin spheres to stimulate mobilization toward the traumas, to ameliorate an inflammatory response of the subject by decreasing an amount of RANTES endothelial production on cytokines production, and/or to improve a secretion of fractalkine. The albumin spheres can be bound with fibrinogen molecules in vitro or in vivo.

The present invention relates to Protoxin-II variants, polynucleotides encoding them, and methods of making and using the foregoing.